Cytoplasmic HuR expression: Correlation with cellular inhibitors of apoptosis protein-2 expression and clinicopathologic factors in oral squamous cell carcinoma cells

Head and Neck

Volumn 36, Issue 8, 2014, Pages 1168-1175

  Cha, Jeong Dan ^a   Kim, Hee Kyeong ^b   Cha, In Ho ^a  

^a Yonsei University College of Dentistry   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

cellular inhibitors of apoptosis protein 2 (cIAP2); HuR; inhibitors of apoptosis proteins; mRNA stability; oral squamous cell carcinoma

Indexed keywords

HUR PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN 2; LEPTOMYCIN B; SMALL INTERFERING RNA; BIRC3 PROTEIN, HUMAN; HU ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN;

ADULT; APOPTOSIS; ARTICLE; CANCER CELL; CLINICAL ASSESSMENT; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOPLASM; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; AGED; CULTURE TECHNIQUE; GENETIC TRANSFECTION; METABOLISM; MIDDLE AGED; MORTALITY; MOUTH TUMOR; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SOUTH KOREA; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR CELL LINE; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CYTOPLASM; FEMALE; HU PARANEOPLASTIC ENCEPHALOMYELITIS ANTIGENS; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MIDDLE AGED; MOUTH NEOPLASMS; REPUBLIC OF KOREA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL RATE; TRANSFECTION;

EID: 84904270337     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.23431     Document Type: Article

References (34)

1. Bagan J, Sarrion G, Jimenez Y,. Oral cancer: clinical features. Oral Oncol 2010; 46: 414-417.
2. Bell RB, Kademani D, Homer L, Dierks EJ, Potter BE,. Tongue cancer: is there a difference in survival compared with other subsites in the oral cavity? J Oral Maxillofac Surg 2007; 65: 229-236.
3. de Araújo RF Jr, Barboza CA, Clebis NK, de Moura SA, Lopes Costa Ade L,. Prognostic significance of the anatomical location and TNM clinical classification in oral squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2008; 13: E344-E347.
4. LaCasse EC, Baird S, Korneluk RG, MacKenzie AE,. The inhibitors of apoptosis (IAPs) and their emerging role in cancer. Oncogene 1998; 17: 3247-3259.
5. Yang YL, Li XM,. The IAP family: endogenous caspase inhibitors with multiple biological activities. Cell Res 2000; 10: 169-177.
6. Snipas SJ, Stennicke HR, Riedl S, et al. Inhibition of distant caspase homologues by natural caspase inhibitors. Biochem J 2001; 357 (Pt 2): 575-580.
7. Langemeijer SM, de Graaf AO, Jansen JH,. IAPs as therapeutic targets in haematological malignancies. Expert Opin Ther Targets 2008; 12: 981-993.
8. Tamm I, Wang Y, Sausville E, et al. IAP-family protein survivin inhibits caspase activity and apoptosis induced by Fas (CD95), Bax, caspases, and anticancer drugs. Cancer Res 1998; 58: 5315-5320.
9. Endo T, Abe S, Seidlar HB, et al. Expression of IAP family proteins in colon cancers from patients with different age groups. Cancer Immunol Immunother 2004; 53: 770-776.
10. Nemoto T, Kitagawa M, Hasegawa M, et al. Expression of IAP family proteins in esophageal cancer. Exp Mol Pathol 2004; 76: 253-259.
11. Tanimoto T, Tsuda H, Imazeki N, et al. Nuclear expression of cIAP-1, an apoptosis inhibiting protein, predicts lymph node metastasis and poor patient prognosis in head and neck squamous cell carcinomas. Cancer Lett 2005; 224: 141-151.
12. Brennan CM, Steitz JA,. HuR and mRNA stability. Cell Mol Life Sci 2001; 58: 266-277.
13. Nabors LB, Gillespie GY, Harkins L, King PH,. HuR, a RNA stability factor, is expressed in malignant brain tumors and binds to adenine- and uridine-rich elements within the 3 untranslated regions of cytokine and angiogenic factor mRNAs. Cancer Res 2001; 61: 2154-2161.
14. Lu JY, Schneider RJ,. Tissue distribution of AU-rich mRNA-binding proteins involved in regulation of mRNA decay. J Biol Chem 2004; 279: 12974-12979.
15. Trzaska D, Dastych J,. [Role of AURE sequences in the regulation of mRNA stability]. [Article in Polish] Postepy Biochem 2005; 51: 28-35.
16. Dean JL, Sully G, Wait R, Rawlinson L, Clark AR, Saklatvala J,. Identification of a novel AU-rich-element-binding protein which is related to AUF1. Biochem J 2002; 366 (Pt 3): 709-719.
17. Lõpez de Silanes I, Lal A, Gorospe M,. HuR: post-transcriptional paths to malignancy. RNA Biol 2005; 2: 11-13.
18. Heinonen M, Fagerholm R, Aaltonen K, et al. Prognostic role of HuR in hereditary breast cancer. Clin Cancer Res 2007; 13: 6959-6963.
19. Cha JD, Li S, Cha IH,. Association between expression of embryonic lethal abnormal vision-like protein HuR and cyclooxygenase-2 in oral squamous cell carcinoma. Head Neck 2011; 33: 627-637.
20. Kim CW, Kim HK, Vo MT, et al. Tristetraprolin controls the stability of cIAP2 mRNA through binding to the 3UTR of cIAP2 mRNA. Biochem Biophys Res Commun 2010; 400: 46-52.
21. Lee SK, Kim SB, Kim JS, et al. Butyrate response factor 1 enhances cisplatin sensitivity in human head and neck squamous cell carcinoma cell lines. Int J Cancer 2005; 117: 32-40.
22. Li S, Kim JS, Kim JM, et al. Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2006; 65: 705-712.
23. Baykul T, Yilmaz HH, Aydin U, Aydin MA, Aksoy M, Yildirim D,. Early diagnosis of oral cancer. J Int Med Res 2010; 38: 737-749.
24. Kreppel M, Eich HT, Kübler A, Zöller JE, Scheer M,. Prognostic value of the sixth edition of the UICC's TNM classification and stage grouping for oral cancer. J Surg Oncol 2010; 102: 443-449.
25. Marocchio LS, Lima J, Sperandio FF, Corrêa L, de Sousa SO,. Oral squamous cell carcinoma: an analysis of 1,564 cases showing advances in early detection. J Oral Sci 2010; 52: 267-273.
26. Miura K, Karasawa H, Sasaki I,. cIAP2 as a therapeutic target in colorectal cancer and other malignancies. Expert Opin Ther Targets 2009; 13: 1333-1345.
27. Jiménez-Lara AM, Aranda A, Gronemeyer H,. Retinoic acid protects human breast cancer cells against etoposide-induced apoptosis by NF-kappaB-dependent but cIAP2-independent mechanisms. Mol Cancer 2010; 9: 15.
28. Gill C, Dowling C, O'Neill AJ, Watson RW,. Effects of cIAP-1, cIAP-2 and XIAP triple knockdown on prostate cancer cell susceptibility to apoptosis, cell survival and proliferation. Mol Cancer 2009; 8: 39.
29. Yoo PS, Sullivan CA, Kiang S, et al. Tissue microarray analysis of 560 patients with colorectal adenocarcinoma: high expression of HuR predicts poor survival. Ann Surg Oncol 2009; 16: 200-207.
30. Wang J, Wang B, Bi J, Zhang C,. Cytoplasmic HuR expression correlates with angiogenesis, lymphangiogenesis, and poor outcome in lung cancer. Med Oncol 2011; 28 Suppl 1: S577-S585.
31. Heinonen M, Bono P, Narko K, et al. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma. Cancer Res 2005; 65: 2157-2161.
32. Cheung HH, Plenchette S, Kern CJ, Mahoney DJ, Korneluk RG,. The RING domain of cIAP1 mediates the degradation of RING-bearing inhibitor of apoptosis proteins by distinct pathways. Mol Biol Cell 2008; 19: 2729-2740.
33. Ishimaru D, Ramalingam S, Sengupta TK, et al. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. Mol Cancer Res 2009; 7: 1354-1366.
34. Sengupta TK, Bandyopadhyay S, Fernandes DJ, Spicer EK,. Identification of nucleolin as an AU-rich element binding protein involved in bcl-2 mRNA stabilization. J Biol Chem 2004; 279: 10855-10863.